Zlepšení kvality léčby depresí a efektivity nákladů s tím spojených
Náklady na léčení depresí v Litvě rostou převážně z důvodu nárůstu recidiv. Výskyt recidivujících depresí je ve značné míře závislý na kvalitě zdravotnické péče následující po diagnostikování depresivního onemocnění. Proto cílem práce bylo hodnocení léčby depresí diagnostikovaných poprvé a používání antidepresiv na základě názorů tří skupin odborníků. Pro tento účel bylo v roce 2009 dotazováno v Litvě 361 farmaceutů, 317 rodinných lékařů a 280 psychiatrů. Data o diagnostikovaných depresích byla získána z Republikového centra psychiatrického zdraví. Za sledované období (2004–2009) vzrostl celkový počet diagnostikovaných depresí o 12 %, počet recidiv pak o 27 %. Jak vyplývá z odpovědí rodinných lékařů, jen 13 % z nich si netroufne zahájit léčbu sami; v případě recidiv posílá pacienty k psychiatrovi 62 % lékařů. Ti, co ordinují léčbu samostatně, nejčastěji předepisují sertralin, avšak až 38 % rodinných lékařů uvádí, že používají k terapii benzodiazepiny, 32 % rodinných lékařů vyhodnocuje účinnost medikamentózní léčby po 4 týdnech, na druhou stranu 25 % z nich takové sledování neprovádí vůbec. Získané výsledky o rozdílech a efektivitě odborné péče zpochybňují kvalitu léčby depresí v Litvě. Je proto zapotřebí vypracovat doporučení vedoucí k následné úpravě a racionalizaci léčby tohoto onemocnění.
Liubov Kavaliauskienė1; Rimantas Pečiūra1; Virginija Adomaitienė2; Ruta Masteiková3
Authors place of work:
Lithuanian University of Health Sciences, Medical Academy, Faculty of Pharmacy, Department of Drug Technology and Social Pharmacy, Lithuania1; Lithuanian University of Health Sciences, Medical Academy, Department of Psychiatry, Kaunas, Lithuania2; University of Veterinary and Pharmaceutical Sciences Brno, Faculty of Pharmacy, Department of Pharmaceutics, Czech Republic3
Published in the journal:
Čes. slov. Farm., 2011; 60, 159-164
Přehledy a odborná sdělení
Cost of depression treatment in Lithuania increases depending mainly on depression relapse rates. Depression relapse is in a great extent conditional on the quality of health care after the disease was diagnosed. This study was thus aimed to evaluate the first-time depression treatment and antidepressants use according to three specialists groups opinion. For this purpose 361 pharmacists, 317 family doctors and 280 psychiatrists were interviewed in Lithuania in 2009. The data on depression diagnoses were obtained from the Republic Psychiatric Health Centre. The volume of total depression diagnoses grew up by 12% during the period under study (2004–2009), the amount of relapsed depression diagnoses by 27%. According to family doctors’ opinion, 13% of respondents still do not initiate depression treatment by themselves and 62% of them refer patients to psychiatrists if depression relapses. Those who prescribe a medicament all alone in most cases use sertraline, but even 38% of family doctors mention benzodiazepines. According to family doctors’ answers, 32% of respondents re-evaluate the effect of medicaments in 4 weeks; on the other hand, 25% of them do not carry out such monitoring at all. The obtained results about the differences and efficiency of professional care question the quality of depression treatment in Lithuania. It is therefore necessary to formulate recommendations leading to corrections and rationalization of depression treatment.
ranks among the most common of chronic health problems. It is also associated
with higher societal costs than many other chronic diseases, especially in
terms of patients’ severe limitations in daily functioning and well-being.
Despite the existence of medical practice guidelines (which specify the most
efficacious therapies for major depressive disorder) patient care varies widely
and many patients do not receive appropriate care.
a series of recent studies, the present authors examined the quality and
cost-effectiveness of care for severely depressed patients treated under
different payment systems by general medical clinicians and mental health care
professionals (psychiatrists, psychologists and master’s-level therapists). The
conclusion was that overall quality of care for depression is less than
optimal, and the cost-effectiveness of care as currently delivered is low.
Among seriously depressed patients, many do not receive appropriate care even
in the mental health speciality sector, but instead receive care for some
problem other than depression or receive treatments that are ineffective for
depression. Such mistakes are wasteful of resources: the health care system could
get far higher returns for the money it spends treating depressed patients by
spending a little more to improve the quality of care – that is, by
appropriately treating more of the depressed patients who are already receiving
some care anyway. This potential for improving cost-effectiveness of care is
especially great for depressed patients who visit general medical providers
such as internists or family doctors1).
prevalence of mental disorders in Lithuania reached only 4.6% among total
population in 2004, of which 0.6% covered for mood (affective) disorders2).
These low ratios and the highest suicide rates in Lithuania in the European
Region3) may lead to a discussion whether the recognition and
the treatment of depression is sufficient in Lithuania. Consequently it is
important to estimate the consumption of antidepressant drugs that are mostly
used to treat depressive disorders as well as the costs of depression treatment
aspects of depression treatment have already been assessed for a long
time. For example, in 2004, the total expenses of treatment of patients with
various depression forms were estimated to be 118 billion Euros in Europe, or
on average 253 Euros per capita per year4). Early researches showed
that the direct costs for depression treatment accounted for only a small
proportion – about 13% – of total amount of disease-related costs. Annual
spending on depression in the USA is 43.7 billion dollars, and in England and
Wales about 3.4 billion pound sterling. While analysing the costs of disease,
all researches showed that the expenses for medicaments accounted for only
a small part of the direct costs (10–12%) and only 1–2% of total cost of
treatment costs encourage to study and assess whether the treatment is
reasonable. While assessing the rationality of treatment of this disease, the
need of medicaments, psychological support of the patient and cooperation of
his/her relatives and the treating doctor is considered.
costs for the treatment of depression do increase in Lithuania due to the
degree of depression recurrence and accounted for 6.95 million Euros of direct
expenses in 2009. The growing number of depression recurrence in Lithuania
shows the need to analyse the rationality of treatment of primary depression.
objective of this study is to analyse how three groups of professionals –
family doctors, psychiatrists and pharmacists – evaluate the prescription and
usage of antidepressants in Lithuania, seeking to rationalize the usage of
costs of drug treatment and to suggest measures, how to save funds, while
improving the quality of patients’ treatment and life, in the future.
data on total sales of antidepressant drugs in all Lithuanian regions over six
years (2004–2009) were obtained from IMS (Intercontinental Marketing Service)
Health Incorporated. Data were retrieved as units of antidepressant drugs and
costs for the drugs. The system and use was quantified in terms of defined
daily doses (DDDs). The data were calculated by DDD methodology and expressed
in DDDs per 1.000 inhabitants per day. Due to low rates of drug consumption,
the Drug Utilization 95% (DU 95%) was used as the quality indicator of drug
prescribing. The number of drugs contributing to 95% of sales as
a proportion of the total number was calculated for each year.
2009 the following professionals, working in Lithuania, were interviewed: 361
pharmacists or pharmacy technicians (95% CI, n = 5923), 317 family doctors (95%
CI, n = 1822) and 280 psychiatrists (95% CI, n = 1030). The confidence level
(CL) sets the boundaries of the confidence interval (CI), this is
conventionally set at 95% to coincide with the 5% convention of statistical
significance in hypothesis testing. A 95% CI is the interval of which you
are 95% certain that it contains the true population value as it might be
estimated from a much larger study.
survey was selected for data collection: it is perfect for the measurement of
quantitative characteristics. The form of the research sample – the so-called
available cases: data were collected from doctors and pharmacists, visiting
them during their working hours, at their training events, conferences,
contacting them in writing and orally, in medical institutions and pharmacies.
The primary data were encrypted, using SPSS data processing package
Windows/SPSS (Statistical Package for the Social Sciences) 14, and presented
with the help of descriptive statistics.
RESULTS AND DISCUSSION
findings show that the expenditure of antidepressants (ADs) increased from
22.59 mln Litas (in 2004) to 26.85 mln Litas (in 2008) although it decreased to
23.98 mln Litas in 2009 (Fig. 1). The expenditure decrease in 2009 was based on
the antidepressants price decrease because of generic products entering the
market. As it is shown, extremely high costs are for SSRIs that include the
biggest part of all ADs costs (66% in 2004; 54% in 2009). However, in
comparison with the costs of SSRIs, the costs of TCAs are low and declined
modestly over the six years (from 1.19 to 0.59 mln Litas). The costs of other
ADs raised significantly in a certain period as their consumption had been
today’s cost-conscious environment, suggestions for improving the quality of care
are not favourably received because improving quality generally means higher
total health care costs. Value of care, or cost-effectiveness, should be an
equally important consideration. If, for example, an employee can function much
more effectively on the job for a slightly higher investment in treatment,
then the benefits accruing to the employer in terms of increased productivity,
or to patients in terms of increased income and quality of life, would seem to
justify the expenditure. But health plans have little incentive to pick up the
tab for increased treatment costs, because plans realize none of these benefits
directly, but instead they are under pressure from employers to keep treatment
costs down. This research points to the irony of this dilemma and suggests that
cost-effectiveness has an important place in the debate.
should be noted that in 2007 the right to diagnose depression and to prescribe
treatment was given to family doctors in Lithuania. According to their
responses in the questionnaire, it is evident that in slightly more than one
tenth of the cases family doctors refrain from prescription of treatment by
themselves (Fig. 2).
While prescribing antidepressants, family doctors
usually choose sertraline – a medicament of the SSRI (selective serotonin
reuptake inhibitors) class (24.9%), in the second and third place bromazepam
(16.7%) and alprazolam (21.2%) – medicaments of the benzodiazepine class – are
mentioned (Fig. 3). There were 15 antidepressants molecules in 2009 in
Lithuania, the choice of which depends on family doctor’s or psychiatrist’s
decision. However, in accordance with the recommendation of depression
treatment and the priority of antidepressants selection in Lithuania, the drug
of choice for the treatment of depression should be amitriptyline, unless
tricyclic antidepressants (TCAs) are contraindicated in a patient and/or
his/her age is under 18 years or more than 65 years. In view of the big
proportion of the SSRI drugs mentioned by respondents, the use of
antidepressants was not consistent with the recommendations for the treatment
of depression in Lithuania. Due to high toxicity of TCAs, these antidepressants
are used less frequently and for a shorter period than recommended6).
questioning psychiatrists the tendency to prescribe medicine of SSRI group,
i.e., sertraline (40.8%) and escitalopram (27.6%), more often showed up, the
third most frequently chosen medicine is mirtazapine (9.2%) (Fig. 3).
survey of pharmacists confirmed the popularity of antidepressants of SSRI class
and other more recent antidepressants (Fig. 3). However, it is important to
highlight that even 13% mentioned alprazolam, bromazepal and lorazepam,
ascribed to the benzodiazepine class. Attention should be paid to the selection
of medicaments prescribed for depression treatment by family doctors: the drugs
of the benzodiazepine group are not suitable for depression treatment, they are
more often prescribed in the cases of anxiety7). The worst is that
the preparations of the benzodiazepine class can stimulate suicide8).
The next stage of depression treatment after drug
prescription is monitoring a patient’s condition. When treating the
starting or acute depression, the impact of medicine should be noticed after 4
weeks already, and the improvement of the disease course after 8 weeks9).
A third of the surveyed Lithuanian family doctors indicated that they review
the impact of different medicine after 1–2 months, 17% – only after half
a year (Fig. 4).
said that they always or often adjust the dose of medicine for almost half of
patients during treatment (27% and 34%, respectively). This emphasizes
a higher quality of patient’s monitoring by these professionals and higher
effectiveness of depression treatment.
proportion of the cases of depression recurrence is large in Lithuania. Our
survey data correlate well with the depression epidemiology data of the State
Mental Health Centre. This is confirmed by both surveys of family doctors and
psychiatrists: about 35% of respondents of both groups indicated recording the
cases of recurrent depression; however, the numbers of cases of recurrent depression
differ significantly (Fig. 5).
analyzing the results of the above responses, conclusions can be made about the
working efficiency of family doctors and psychiatrists and the appropriate
proposals might be put forward, saving funds and seeking economic and social
diagnosing a recurrent depression, family doctors refer patients to
psychiatrists immediately (61.7% of cases). When meeting the mentioned
patients, psychiatrists prescribe the medicament, which has been prescribed
earlier, even in 73.36% of cases.
This research suggests that for the improvement of the
quality of care for depression it is necessary to raise the value of care and
enhance the benefit of treatment dollars. From a patient’s perspective,
quality improvement leads to better patient functioning, and this benefit could
increase patient’s satisfaction, which could be meaningful to plans competing
with other plans for enrolment.
majority of surveyed psychiatrists have a relatively long working
experience. However, experienced professionals probably not always evaluate the
causes of depression carefully. For example, during this period of physical
beauty cult, the cause of depression may be obesity10), experienced
serious diseases11), etc.
treating a person with recurrent depression, the disease should be looked
into even more closely: the reasons for recurrence of depression may be not
only inappropriately selected medicament or incorrectly identified diagnosis12),
but also too early terminated earlier treatment, newly arising psychological
problems, the changed social status, etc.13). In particular it is
important to communicate frequently with the patient, to monitor his/her
condition at the beginning of treatment and to react in time, if there are no
signs of improvement in appropriate time14).
addition, providing high-quality care that leads to better functioning outcomes
creates benefits for many other parties not involved in health care.
The consideration of who benefits from improved quality
of care implies, however, that patients and employers would be able to
attribute the benefits they accrue from better care to that care, or would
otherwise have the necessary information to determine whether a plan or
practice that claims to provide higher-quality care actually does so and is
worth the additional expense1). Unfortunately, this is currently not
the case, and better measures of quality and accountability are needed.
studies and experience of professionals show that medicaments are not enough
for depression treatment – a combination of an individually selected drug
and psychological help is needed. Family doctors and psychiatrists with
a long-time experience should re-evaluate the changed context and causes
of depression and cooperate more closely with pharmacists, seeking to find out
about the latest antidepressants.
abundance of cases of recurrent depression, especially recorded by family
doctors, who have already treated the same patients with depression earlier,
encourage to look at the instruction of family doctors to treat this disease
anew. It is recommended to provide more information and trainings, regarding
depression, to doctors. It should also be encouraged to refer the persons with
depression to psychiatrists immediately, in order to avoid a long-term
Lithuania, which is a leader in Europe in terms of suicide rates15),
it would be useful to look for links of suicide with its frequent cause –
depression, and to look deeper into the stories of suicides.
It is the
time to evaluate the economic and social impact of depression – treatment costs
are exorbitant, but generally not recorded. In the case of the evaluation of
this factor, depression treatment would be considered more carefully and
18 May 2011
Accepted 9 June 2011
Address for correspondence:
Assoc. Prof. Ruta
Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical
Palackého 1/3, 612 42
Brno, Czech Republic
1. Improving the Quality and Cost-Effectiveness of Treatment for Depression http://www.rand.org/pubs/ research_briefs/RB4500-1/index1.html (2011.04.18)
2. Data from the State Centre of Mental Health, http://www.vpsc.lt (2010.12.10)
3. WHO Highlights on Health in Lithuania, March 2001, http://europa.eu.int/comm/health/ph_projects/1999/monitoring/lithuania_en.pdf
4. Sobocki, P., Jönsson, B., Angst, J., Rehnberg, C.: Cost of depression in Europe. J. Mental Health Policy Econ. 2006; 9(2), 87–98.
5. Neverauskas, J.: Ekonomiškai efektyvus depresijos gydymas [Cost-effective depression treatment]. Nervų ir psichikos ligos [Nervous and mental diseases], 2003; 1. http://www.medicine.lt/index.php?pagrid=leidiniai&subid=npl&strid=128 (2011.03.10).
6. Kavaliauskienė, L., Pečiūra, R., Adomaitienė, V., Masteiková, R.: Depression relapse and antidepressants consumption in quality of life aspect. Čes. slov. Farm. 2010; 59, 199–204.
7. Norkus, R., Macevičius, G.: Benzodiazepinų reikšmė gydant pacientus, sergančius depresija ir nerimo sutrikimais [Role of benzodiazepines in depression and anxiety disorders treatment]. Nervų ir psichikos ligos [Nervous and mental diseases], 2007; 6. http://www. medicine.lt/index.php?pagrid=leidiniai&subid=npl&strid=7016 (2010.08.15).
8. Bobrow, R. S.: Benzodiazepines revisited. Family Practice 2003; 20, 347–349.
9. Thase, M. E.: Achieving remission and managing relapse in depression. J Clin Psychiatry 2003; 64(Suppl 18), 3–7.
10. Luppino, F., de Wit, L., Bouvy, P., Stijnen, T., Cuijpers, P., Penninx, B., Zitman, F.: Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies. Arch. Gen. Psychiatry 2010; 67(3), 220–229.
11. Poynter, B., Shuman, M., Diaz-Granados, N., Kapral, M., Grace, S. L., Stewart, D. E.: Sex differences in the prevalence of post-stroke depression: a systematic review. Psychosomatics 2009; 50(6), 563–569.
12. Mann, J. J.: The medical management of depression. N. Engl. J. Med. 2005; 353, 1819–1834.
13. Recovery and relapse prevention. Centre for Addiction and Mental Health. http://www.camh.net/About_Addic tion_Mental_Health/Mental_Health_Information/Depressive_Illness/dep_illness_relapse.html (2010.12.17).
14. What is the general approach to treating depression? http://www.medicinenet.com/depression/page7.htm (2010.06.12).
15. Lietuva pirmauja savižudybių skaičiumi regione [Lithuania is the first in suicide rates in region]. http:// www.vtv.lt/naujienos/nusikaltimai/lietuva-pirmauja-savizudybiu-skaiciumi-regione.html (2010.06.10)